MMV’s strategy to contain antimalarial resistance includes:
- the development of patient friendly medicines, including children’s formulations that improve adherence to treatment and clinical effectiveness, which reduce the probability of resistance;
- the development and delivery of only high-quality, WHO-prequalified medicines;
- the development of discovery networks and assay platforms to accelerate the identification of the most promising compounds against malaria as well as drug-resistant strains of many other pathogens;
- support to national malaria programmes and other partners to deliver the right medicine to the right patient at the right time.